A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations
Not Applicable
- Conditions
- lung adenocarcinoma
- Registration Number
- JPRN-UMIN000002783
- Lead Sponsor
- agano lung cancer study meeting
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1)interstitial pneumonia on computed tomography scan 2)liver cirrhosis, uncontrolled diabetes mellitus, cardiac infarciton and cereral apoplexy onset within three months 3)othere active cancer 4)symptomatic brain metastases 5)need to plan the radiotherapy included in the lung field 6)history of sever drug allegy 7)judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method safety, disease control rate, progression free survival overall survival, quality of life